List of Excipients in Branded Drug AMICAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Akorn Operating Company LLC	AMICAR	aminocaproic acid	49411-052	ANHYDROUS CITRIC ACID
Akorn Operating Company LLC	AMICAR	aminocaproic acid	49411-052	EDETATE DISODIUM
Akorn Operating Company LLC	AMICAR	aminocaproic acid	49411-052	METHYLPARABEN
Akorn Operating Company LLC	AMICAR	aminocaproic acid	49411-052	PROPYLPARABEN

AMICAR Excipient Strategy and Commercial Opportunities for Aminocaproic Acid

Last updated: August 23, 2026

Amicar is the branded formulation of aminocaproic acid, an antifibrinolytic used to reduce bleeding by inhibiting plasminogen activation and plasmin activity. Its commercial value is concentrated in hospital injectable use, oral liquid delivery, perioperative bleeding management, and generic supply continuity rather than in a broad, active brand patent estate. Excipient innovation can improve pediatric use, palatability, preservative systems, storage stability, IV handling, and differentiated packaging.

What is Amicar and how is it used?

Amicar contains aminocaproic acid, a synthetic lysine analogue administered orally or intravenously. FDA labeling identifies indications involving excessive fibrinolysis, including certain surgical, hematologic, and urinary tract bleeding settings.[1]

Amicar dosage forms

Dosage form	Typical strength	Primary commercial setting	Excipient priorities
Oral solution	0.25 g/mL	Acute and chronic oral dosing; pediatric and institutional use	Taste masking, preservative control, chemical stability, dosing accuracy
Tablets	500 mg and 1,000 mg historically marketed	Adult outpatient and institutional use	Swallowability, compact dose delivery, low-cost manufacture
Injection	250 mg/mL	Hospital and perioperative use	Sterility, osmolality, container compatibility, IV handling
Generic products	Product-specific	Hospital and retail channels	ANDA bioequivalence, supply reliability, COGS control

Aminocaproic acid is highly water soluble, which supports concentrated oral and injectable products. That solubility reduces the need for complex solubilization systems but creates formulation risks involving taste, osmotic load, pH control, preservative selection, and container compatibility.

What excipients are used in Amicar formulations?

The exact inactive ingredient profile depends on dosage form and manufacturer. FDA labeling and product-specific DailyMed records should control any final excipient assessment because generic aminocaproic acid products can use different excipient systems.[1,2]

Oral solution excipient strategy

An aminocaproic acid oral solution generally requires excipients in five functional groups:

1. Vehicle and tonicity modifiers.
2. Sweeteners and flavors.
3. Preservatives.
4. pH-adjusting agents and buffers.
5. Chelators or stabilizers where justified by compatibility data.

The central formulation problem is taste. Aminocaproic acid has a strong, saline or bitter taste that can reduce adherence, especially in children and patients receiving repeated doses. A successful oral liquid does not need a complex excipient platform. It needs a reproducible taste-masking system that does not compromise assay, microbial quality, or dosing uniformity.

Potential excipient approaches include:

• High-intensity sweeteners such as sucralose or sodium saccharin.
• Polyols such as sorbitol or glycerin, subject to gastrointestinal tolerability.
• Fruit or berry flavors selected for compatibility with the active ingredient.
• Viscosity modifiers that increase residence time in the mouth.
• Preservatives appropriate for the target pH and packaging system.
• Unit-dose oral syringes to improve administration accuracy.

A formulation developer should avoid excessive sugar loading. Hospitals and pediatric caregivers may prefer sugar-free products, while polyol-heavy systems can produce gastrointestinal effects and complicate use in patients receiving high daily volumes.

Tablet excipient strategy

Tablets provide a lower-cost, portable alternative to liquid dosing. The main constraints are the relatively high dose and the need for rapid, reliable disintegration.

A 1,000 mg tablet may be large for pediatric patients, older adults, and patients with postoperative swallowing difficulty. Commercial opportunities include:

• Smaller-dose tablets for titration.
• Scored tablets for flexible dosing.
• Film coatings that reduce mouth contact and improve swallowability.
• Immediate-release formulations with robust disintegration.
• High-load direct-compression systems that reduce manufacturing steps.
• Unit-dose blister packaging for hospital medication administration.

Common tablet excipient categories may include diluents, binders, disintegrants, lubricants, and film-coating materials. The preferred system depends on powder flow, tablet hardness, dissolution performance, and the high active load of aminocaproic acid.

A multilayer or extended-release tablet is less attractive unless a clear clinical need exists. Amicar dosing is generally linked to the timing and persistence of fibrinolysis, and a modified-release product would require new pharmacokinetic and clinical justification.

What excipient strategies create the strongest commercial opportunities?

The highest-value opportunities are dosage-form improvements that solve an operational problem without requiring a new clinical indication.

1. Sugar-free, palatable oral solution

A sugar-free oral solution could target pediatric hospitals, hematology clinics, dental surgery, and outpatient perioperative care. The commercial proposition would depend on:

• Demonstrated taste acceptance.
• Low sedimentation and consistent dose delivery.
• Preservative efficacy through the labeled shelf life.
• Compatibility with oral syringes.
• Protection against microbial contamination after opening.
• Reduced staining or residue on administration equipment.

A dual-flavor strategy could support pediatric and adult use without creating multiple active-ingredient strengths.

2. Ready-to-use unit-dose oral liquid

Unit-dose cups or prefilled oral syringes could reduce medication errors and contamination after opening. This approach is particularly relevant where patients receive repeated doses over a short period.

The opportunity is strongest if the product can offer:

• No measurement by caregivers.
• Clear dose labeling.
• Tamper evidence.
• Low fill-volume variability.
• Reduced exposure to repeated bottle opening.
• Packaging compatible with automated hospital dispensing.

The trade-off is higher packaging cost and more complex supply-chain logistics.

3. Preservative-free or low-preservative injectable product

A preservative-free injectable presentation could appeal to hospitals that limit preservative exposure in vulnerable patient populations. The product would need sterile manufacturing, validated container closure integrity, and a clear in-use stability position.

Commercial differentiation could come from:

• Ready-to-administer bags.
• Pharmacy-prepared infusion containers.
• Single-dose vials with reduced overfill.
• Plastic containers compatible with standard infusion systems.
• Clear labeling for dilution and administration.

The principal barrier is manufacturing cost. Injectable aminocaproic acid is a hospital product, so supply reliability, shortage avoidance, and pharmacy workflow may matter more than minor formulation differences.

4. Ready-to-use IV presentations

Aminocaproic acid injection commonly requires pharmacy handling or dilution according to institutional protocols. A ready-to-use presentation could reduce compounding time and preparation errors.

Possible formats include:

Format	Commercial benefit	Principal barrier
Premixed infusion bag	Reduces pharmacy preparation	Larger manufacturing and shipping footprint
Prefilled syringe	Fast administration in procedural settings	Device compatibility and stability
Small-volume vial	Flexible dosing	Continued dilution and preparation burden
Dual-chamber system	Separates unstable components until use	High development and packaging cost

A ready-to-use bag is more likely to gain institutional traction than a technically complex dual-chamber system because the active ingredient itself is relatively simple and highly soluble.

5. Pediatric dosing platform

Pediatric use is a strong target for excipient-led differentiation. A product could combine a palatable liquid, oral syringe, age-based dose markings, and a preservative system designed for repeated short-term administration.

The regulatory burden would depend on whether the product is a pharmaceutical equivalent of an approved reference product or a materially different formulation requiring additional clinical support. Taste claims must be supported by suitable sensory or human-factor data rather than inferred from excipient selection.

What formulation patents could protect an Amicar product?

The strongest formulation patent opportunities would generally involve a defined excipient combination, stability profile, delivery device, or manufacturing process rather than aminocaproic acid itself.

Potential claim categories include:

• A specific sweetener-flavor-preservative combination.
• A pH range that improves stability and taste.
• A low-sugar or sugar-free oral solution with defined microbial limits.
• A concentrated oral solution with reduced precipitation or crystallization.
• A ready-to-use injectable composition with specified osmolality.
• A container-closure system that preserves potency after opening.
• A prefilled oral syringe or IV delivery system.
• A manufacturing process that reduces bioburden or improves batch uniformity.

A formulation patent would need meaningful technical differentiation. Broad claims covering aminocaproic acid in a conventional aqueous vehicle would face vulnerability from routine formulation practices and prior art.

How strong is the patent estate for Amicar?

Amicar is a legacy product, and the principal commercial barrier is unlikely to be a broad, long-dated composition-of-matter patent. Aminocaproic acid itself has been used clinically for decades. Market protection is more likely to depend on:

• Regulatory approval status.
• Manufacturing capability.
• Hospital contracting.
• Product availability.
• Injectable quality systems.
• Formulation-specific patents, if any remain enforceable.
• Trade secrets involving process control and packaging.

The Orange Book should be reviewed for current listed patents associated with the relevant reference product and NDA. Generic applicants may address listed patents through Paragraph IV certifications where applicable.[3]

When does Amicar lose exclusivity?

Amicar’s original exclusivity period has long expired. Aminocaproic acid products are generally exposed to generic competition, subject to product-specific FDA approval, market availability, and any surviving formulation or method-of-use rights.

Protection category	Amicar position
New chemical entity exclusivity	Expired
Original product patent protection	Historical and generally expired
Current generic competition	Present or potentially available by dosage form
Pediatric exclusivity	Not expected to provide current market protection
Orphan exclusivity	Not a general basis for broad Amicar protection
Biosimilar pathway	Not applicable because aminocaproic acid is a small molecule
Paragraph IV risk	Relevant only to active Orange Book-listed patents
Regulatory exclusivity	Product-specific and should be verified in FDA records

A competitor should not assume that the absence of a broad patent estate eliminates all legal risk. Method-of-use patents, formulation patents, device patents, and manufacturing patents can create narrower barriers. Their practical value depends on claim scope, enforceability, listing status, and whether the target use is carved out of labeling.

What is the Orange Book status of Amicar?

The Orange Book identifies approved drug products and, where applicable, patent and exclusivity information. Amicar-related status must be assessed by matching the exact NDA, dosage form, strength, and current reference-listed-drug designation.[3]

For a generic entrant, the critical questions are:

1. Is the target product designated as a reference listed drug?
2. Are any patents currently listed for the relevant product?
3. Are the patents expired, delisted, or subject to regulatory use codes?
4. Can a proposed label omit the patented method of use?
5. Does the applicant need a Paragraph IV certification?
6. Is a 30-month stay possible under the Hatch-Waxman framework?

Because aminocaproic acid has multiple dosage forms and generic manufacturers, an applicant should treat oral solution, tablets, and injection as separate regulatory and commercial markets.

Which companies are challenging or competing with Amicar?

Competition comes primarily from generic manufacturers rather than biosimilar developers. Potential competitors include manufacturers with approved aminocaproic acid tablets, oral solutions, or injections, as well as hospital suppliers and contract manufacturers.

The competitive landscape includes:

• Generic oral solid-dose manufacturers.
• Injectable generic manufacturers with sterile capacity.
• Specialty pharmaceutical companies supplying antifibrinolytics.
• Hospital-focused distributors.
• Compounding pharmacies, where legally permitted and clinically appropriate.
• Alternative antifibrinolytics such as tranexamic acid.

Tranexamic acid is the most important therapeutic comparator. It is widely used in trauma, surgery, obstetrics, and dental bleeding, and often has stronger current clinical visibility. Aminocaproic acid can remain commercially relevant where clinicians prefer its historical use, specific dosing protocols, or availability in a particular dosage form.

How does Amicar compare with tranexamic acid?

Factor	Aminocaproic acid, Amicar	Tranexamic acid
Drug class	Antifibrinolytic lysine analogue	Antifibrinolytic lysine analogue
Main mechanism	Inhibits plasminogen activation and plasmin activity	Inhibits plasminogen activation and plasmin activity
Market maturity	Legacy product with generic exposure	Broad generic use and strong clinical adoption
Pediatric liquid opportunity	Meaningful, especially for taste and dosing	Also meaningful
IV opportunity	Hospital injectable products	Strong hospital and procedural use
Patent moat	Limited for legacy active ingredient	Primarily generic-market economics
Differentiation path	Formulation, packaging, supply reliability	Formulation, dosing convenience, specialty indications
Competitive threat	Tranexamic acid substitution	Established standard in several indications

Aminocaproic acid’s commercial opportunity is therefore selective. A new product must offer a tangible workflow or adherence benefit rather than simply replicate an existing bottle or vial.

What manufacturing and intellectual-property barriers affect Amicar?

Manufacturing barriers differ by dosage form.

Oral products

Oral solutions have relatively low technical complexity but require control of:

• Microbial quality.
• Preservative efficacy.
• Flavor uniformity.
• Container interaction.
• Dose-measurement accuracy.
• Chemical stability during in-use storage.

Tablets require high-dose compression capability, consistent blend uniformity, and acceptable dissolution despite the large active load.

Injectable products

Injectables have a higher barrier because of:

• Sterile manufacturing requirements.
• Endotoxin control.
• Container-closure integrity.
• Particulate control.
• Extractables and leachables assessment.
• In-use and dilution stability.
• Hospital compatibility testing.

This makes sterile manufacturing capacity more commercially valuable than a marginal excipient change. A reliable injectable supplier can win share during shortages, backorders, or hospital conversion events.

What FDA regulatory pathway applies to an Amicar formulation?

A conventional generic version of an approved aminocaproic acid product would generally use the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to establish pharmaceutical equivalence, bioequivalence where applicable, quality, stability, and manufacturing compliance.[4]

A materially differentiated product may require a different pathway or additional evidence. Examples include:

• A new extended-release product.
• A substantially different delivery device.
• A new route of administration.
• A formulation with clinical claims not supported by the reference product.
• A product relying on a new indication or new dosing regimen.

For oral solutions, comparative bioequivalence may be less complex than for solid oral products if the product meets applicable criteria for an aqueous solution. Taste-masking changes still require careful assessment because excipients can affect tolerability, dosing behavior, and product quality.

What licensing and commercial partnership opportunities exist?

The most practical partnership models involve manufacturing, hospital distribution, or packaging rather than licensing a core patent.

Attractive partnership structures

• Licensing a palatable pediatric oral liquid platform.
• Contract manufacturing of sterile aminocaproic acid injection.
• Co-development of ready-to-use IV bags.
• Hospital distribution agreements.
• Private-label supply for regional pharmaceutical companies.
• Acquisition of an approved ANDA with manufacturing transfer.
• Co-packaging with oral syringes and dosing aids.

A buyer should value an Amicar product based on approved dosage forms, manufacturing redundancy, shortage history, gross margin, hospital contracts, and regulatory inspection history. Patent life alone is unlikely to support a high valuation unless a differentiated formulation has enforceable claims and meaningful market adoption.

What generic launch scenarios exist for Amicar?

Low-cost commodity launch

A manufacturer supplies standard tablets or oral solution at a low price. Success depends on COGS, procurement access, and reliable availability. This strategy has limited pricing power.

Pediatric differentiation launch

A company introduces a palatable, sugar-free oral solution with unit-dose administration. The product can command a premium if it reduces medication errors and improves adherence.

Hospital injectable launch

A sterile manufacturer supplies vials or premixed infusion bags. The key commercial advantages are supply continuity, pharmacy convenience, and contract pricing.

Specialty distributor launch

A company targets hematology, surgery, dental, and transplant centers with focused distribution and clinical education. The market is smaller but may support better customer retention.

What revenue exposure does Amicar create?

Revenue exposure depends on product mix rather than total prescription volume.

Revenue driver	Exposure
Standard tablets	High price competition; broad but mature demand
Oral solution	Moderate differentiation potential; stronger pediatric relevance
Injectable vial	Hospital procurement and sterile capacity are decisive
Ready-to-use infusion	Higher potential value per unit; greater development cost
Unit-dose packaging	Premium opportunity; higher packaging expense
Supply contracts	More predictable volume; lower per-unit pricing

The best risk-adjusted opportunity is usually an improved oral liquid or reliable sterile product. A novel release profile would carry higher regulatory and clinical risk without a proportionate commercial advantage.

Key Takeaways

• Amicar is aminocaproic acid, a legacy antifibrinolytic with extensive generic exposure.
• The strongest commercial opportunities are formulation and delivery improvements, not new-molecule patent protection.
• Taste masking, sugar-free oral liquids, unit-dose packaging, and pediatric dosing are credible differentiation paths.
• Injectable products offer higher manufacturing barriers and stronger value for supply reliability.
• Ready-to-use IV presentations could reduce hospital pharmacy workload and medication-preparation risk.
• A formulation patent should claim a specific technical combination or delivery system, not merely aminocaproic acid in water.
• Orange Book, DailyMed, and FDA approval records must be checked by exact dosage form and NDA before making a Paragraph IV or launch decision.
• Tranexamic acid is the principal competitive substitute and limits pricing power for undifferentiated aminocaproic acid products.
• Biosimilar risk is irrelevant because aminocaproic acid is a small-molecule drug.
• Licensing value is most likely to arise from approved ANDAs, sterile manufacturing capacity, packaging technology, or hospital distribution access.

FAQs

Can a sugar-free Amicar oral solution receive premium pricing?

Yes, if it demonstrates better palatability, pediatric usability, dosing accuracy, or storage performance than standard generic products. Sugar-free status alone is unlikely to sustain a large premium.

Is a ready-to-use aminocaproic acid infusion commercially viable?

It can be viable where hospitals face pharmacy labor constraints or injectable supply shortages. The product must justify higher manufacturing and shipping costs through workflow savings or contracting advantages.

Does Amicar require a biosimilar development program?

No. Aminocaproic acid is a small-molecule active ingredient. Generic development generally proceeds through the ANDA pathway rather than the biosimilar pathway.

Can an oral syringe be part of an Amicar product strategy?

Yes. An oral syringe can improve dose accuracy and provide a basis for packaging and device differentiation, particularly for pediatric and liquid-dose use.

What is the most defensible IP for a new aminocaproic acid product?

The most defensible IP is likely to involve a validated excipient combination, stability profile, container system, dosing device, or manufacturing process with measurable technical advantages.

References

1. U.S. Food and Drug Administration. (n.d.). Amicar (aminocaproic acid) prescribing information. FDA.
2. National Library of Medicine. (n.d.). DailyMed: Aminocaproic acid drug labels. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. FDA.